Rubius Therapeutics (NASDAQ: RUBY) reported Q1 EPS of ($0.42), $0.04 worse than the analyst estimate of ($0.38).“Rubius has made significant ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE